PURPOSE: To evaluate results in the palliative treatment of patients with liver metastases of uveal malignant melanoma using transarterial chemoembolization (TACE). MATERIALS AND METHODS: Superselective TACE was repeatedly performed in 12 patients with liver metastases of uveal malignant melanoma. Six patients presented with solitary liver metastases (6-12 cm in size) and six patients with oligonodular metastases (n < or = 6). The embolization suspension consisted of a maximum of 10 mg/m(2) Mitomycin C, 10 ml Lipiodol, and an injection of 200-450 mg resorbable microspheres for vascular occlusion. In the follow-up, magnetic resonance imaging was performed in 3-month intervals. RESULTS: The TACE procedure was well tolerated in all patients without any relevant side effects. Three patients responded to TACE with a size reduction of more than 50% (partial response), five patients with stable disease, and four patients with progressive disease with an increase in volume of more than 25%. Mean survival following primary tumor treatment was 32.9 months, and after first embolization 19.5 months. Lower survival rates were recorded for the progressive group (16.5 months). CONCLUSION: Repeated TACE offers a palliative treatment option in patients with oligonodular liver metastases of uveal malignant melanoma.
PURPOSE: To evaluate results in the palliative treatment of patients with liver metastases of uveal malignant melanoma using transarterial chemoembolization (TACE). MATERIALS AND METHODS: Superselective TACE was repeatedly performed in 12 patients with liver metastases of uveal malignant melanoma. Six patients presented with solitary liver metastases (6-12 cm in size) and six patients with oligonodular metastases (n < or = 6). The embolization suspension consisted of a maximum of 10 mg/m(2) Mitomycin C, 10 ml Lipiodol, and an injection of 200-450 mg resorbable microspheres for vascular occlusion. In the follow-up, magnetic resonance imaging was performed in 3-month intervals. RESULTS: The TACE procedure was well tolerated in all patients without any relevant side effects. Three patients responded to TACE with a size reduction of more than 50% (partial response), five patients with stable disease, and four patients with progressive disease with an increase in volume of more than 25%. Mean survival following primary tumor treatment was 32.9 months, and after first embolization 19.5 months. Lower survival rates were recorded for the progressive group (16.5 months). CONCLUSION: Repeated TACE offers a palliative treatment option in patients with oligonodular liver metastases of uveal malignant melanoma.
Authors: Alexander Schmittel; Ronny Schuster; Nikolaos E Bechrakis; Jan M Siehl; Michael H Foerster; Eckhard Thiel; Ulrich Keilholz Journal: Melanoma Res Date: 2005-10 Impact factor: 3.599
Authors: S Leyvraz; V Spataro; J Bauer; S Pampallona; R Salmon; T Dorval; R Meuli; M Gillet; F Lejeune; L Zografos Journal: J Clin Oncol Date: 1997-07 Impact factor: 44.544
Authors: M Cantore; G Fiorentini; E Aitini; B Davitti; G Cavazzini; C Rabbi; A Lusenti; M Bertani; C Morandi; V Benedini Journal: Tumori Date: 1994-02-28
Authors: Carin F Gonsalves; David J Eschelman; Robert D Adamo; P Rani Anne; Marlana M Orloff; Mizue Terai; Anthony N Hage; Misung Yi; Inna Chervoneva; Takami Sato Journal: Radiology Date: 2019-08-27 Impact factor: 11.105
Authors: K Strobel; B Bode; R Dummer; P Veit-Haibach; D R Fischer; L Imhof; S Goldinger; Hans C Steinert; G K von Schulthess Journal: Eur J Nucl Med Mol Imaging Date: 2009-06-04 Impact factor: 9.236